GSK3B and non-small cell lung carcinoma: In short, our research is the first one to demonstrate that MSJZD restrains EMT through the AKT/GSK3β pathway, thereby repressing the migration and invasion of NSCLC cells, which is expected to become a new therapeutic target for NSCLC.